These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Fowler DH; Gress RE Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730 [TBL] [Abstract][Full Text] [Related]
5. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954 [TBL] [Abstract][Full Text] [Related]
7. Chimerism, the Microenvironment and Control of Leukemia. Deeg HJ Front Immunol; 2021; 12():652105. PubMed ID: 33968052 [TBL] [Abstract][Full Text] [Related]
8. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice. Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029 [TBL] [Abstract][Full Text] [Related]
9. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210 [TBL] [Abstract][Full Text] [Related]
10. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration. Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H Front Immunol; 2021; 12():785774. PubMed ID: 34987512 [TBL] [Abstract][Full Text] [Related]
11. Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Kornblau SM; Aycox PG; Stephens C; McCue LD; Champlin RE; Marini FC Exp Hematol; 2007 May; 35(5):842-53. PubMed ID: 17577932 [TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy. Talmadge JE Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168 [TBL] [Abstract][Full Text] [Related]
13. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Jones SC; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217 [TBL] [Abstract][Full Text] [Related]
14. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation. Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173 [TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]